# Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

> **NCT06785636** · PHASE1,PHASE2 · RECRUITING · sponsor: **Pathos AI, Inc.** · enrollment: 252 (estimated)

## Conditions studied

- mCRPC (Metastatic Castration-resistant Prostate Cancer)
- Genital Neoplasms, Male
- Urogenital Neoplasms
- Urogenital Cancers
- Prostatic Diseases
- Prostatic Neoplasms
- Male Urogenital Diseases
- Neoplasms
- Neoplasms by Site
- Prostate Cancer

## Interventions

- **DRUG:** Pocenbrodib
- **DRUG:** Cohort 2A (Pocenbrodib monotherapy), Cohort 2B (Pocenbrodib + abiraterone acetate), Cohort 2C (Pocenbrodib + olaparib), Cohort 2D (Pocenbrodib + 177Lu-PSMA-617

## Key facts

- **NCT ID:** NCT06785636
- **Lead sponsor:** Pathos AI, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-07
- **Primary completion:** 2028-06-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 252 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06785636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06785636, "Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06785636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*